By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Women's health diagnostic test startup Sera Prognostics today said it has raised $1.4 million in a Series A-1 round, which will go toward development of a test for preterm birth risk.

Leading the A-1 round was UpStart Ventures, which founded Sera in 2008. Catalyst Health Ventures and individual investors also participated in the round. Dennis Farrar, a partner with UpStart, is the company's chairman and CEO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.